Home › Congenital Heart Defects › NCT06434207
Extracellular Vesicle Micro RNA Profiling in Congenital Heart Disease: Fetal-Maternal Regulation in Neonatal Thrombosis
Who can join
1 Day – 7 Days · All sexes
Full eligibility criteria
Inclusion Criteria: * All neonates with a diagnosis of severe Congenital Heart Disease undergoing surgery at Boston Children's Hospital in the first week of life Exclusion Criteria: * None
About the study
Newborns with congenital heart disease (CHD) are at increased risk of developing postpartum and postoperative blood clots after cardiac surgery. The molecular mechanisms that are responsible for the clotting profile predisposing children to blood clots in the early stages of life are currently not well described.
The goal of this proposal is to prospectively collect plasma samples from ten (10) neonates with antenatal diagnosis of severe congenital heart disease (CHD) to better understand mechanisms responsible for abnormal clotting in the perioperative period.
What is being tested
- Collecting discarded blood samples (other)
Sponsor: Boston Children's Hospital · Participants: 10 · Started: Oct 31, 2024
Contact the study team
- Rachel Bernier, MPH · Phone: 857-218-5348
Official record on ClinicalTrials.gov — NCT06434207
Locations in the U.S.
| Massachusetts | Boston Children's Hospital, Boston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.